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BACKGROUND & AIMS:
Histologic analysis of liver biopsy specimens allows for grading and staging of nonalcoholic fatty liver disease (NAFLD). We performed a longitudinal study to investigate the long-term prognostic relevance of histologic features for patients with NAFLD. METHODS: We performed a retrospective analysis of 619 patients diagnosed with NAFLD from 1975 through 2005 at medical centers in the United States, Europe, and Thailand. Patients underwent laboratory and biopsy analyses, and were examined every 3-12 months after their diagnosis. Outcomes analyzed were overall mortality, liver transplantation, and liver-related events. Cumulative outcomes were compared by log-rank analysis. Cox proportional-hazards regression was used to estimate adjusted hazard ratios (HRs). Time at risk was determined from the date of liver biopsy to the date of outcome or last follow-up examination. RESULTS: Over a median follow-up period of 12.6 years (range, 0.3-35.1 y), 193 of the patients (33.2%) died or underwent liver transplantation. Features of liver biopsies significantly associated with death or liver transplantation included fibrosis stage 1 (HR, 1.88; 95% confidence interval [CI], 1.28-2.77), stage 2 (HR, 2.89; 95% CI, 1.93-4.33), stage 3 (HR, 3.76; 95% CI, 2.40-5.89), and stage 4 (HR, 10.9; 95% CI, 6.06-19.62) compared with stage 0, as well as age (HR, 1.07; 95% CI, 1.05-1.08), diabetes (HR, 1.61; 95% CI, 1.13-2.30), current smoking (HR, 2.62; 95% CI, 1.67-4.10), and statin use (HR, 0.32; 95% CI, 0.14-0.70). Twenty-six patients (4.2%) developed liver-related events; fibrosis stage 3 (HR, 14.2; 95% CI, 3.38-59.68) and stage 4 (HR, 51.5; 95% CI, 9.87-269.2) compared with stage 0, were associated significantly with the events. Patients with fibrosis, regardless of steatohepatitis or NAFLD activity score, had shorter survival times than patients without fibrosis. CONCLUSIONS: In a longitudinal study of patients with NAFLD, fibrosis stage, but no other histologic features of steatohepatitis, were associated independently with long-term overall mortality, liver transplantation, and liver-related events.
Keywords: NASH; Prognosis; PRELHIN Study; Prediction. N onalcoholic fatty liver disease (NAFLD) represents the most common chronic liver condition around the world. The disease encompasses a wide range of liver pathology with some patients presenting with steatosis and no additional features of liver injury whereas other patients present with nonalcoholic steatohepatitis (NASH) with or without fibrosis or cirrhosis. 1 This range of liver pathology does not necessarily imply that individuals with steatosis are at risk for NASH or advanced fibrosis or that patients with NASH inevitably will progress to cirrhosis. Nevertheless, some patients with NAFLD may develop cirrhosis and die from complications of portal hypertension, liver failure, and hepatocellular cancer (HCC) [2] [3] [4] [5] if liver transplantation is not performed. Currently, NAFLD represents a common cause of liver transplantation, and even the second most common cause of liver transplantation in large medical centers. 6 Despite this clinical reality, the long-term prognosis of patients with NAFLD remains incompletely elucidated. When compared with the general population of the same age and sex, patients with NAFLD have a significantly higher mortality rate. 7 However, the long-term prognosis is not the same across the spectrum of the disease. Patients with steatosis and minimal or no additional features of liver injury may follow a relatively benign clinical course with overall mortality similar to the general population of similar age and sex, 8 whereas in patients with NASH the long-term mortality seems greater than in the general population of the same age and sex. 9 Unfortunately, studies on NASH confirmed by liver biopsy reported to date 9, 10 have included small numbers of patients, and used a definition of NASH that is different from currently accepted criteria, 11, 12 precluding meaningful conclusions. 13, 14 Liver biopsy in patients with suspected NAFLD allows confirmation of the diagnosis, and, more importantly, grading and staging the disease. The NAFLD activity score (NAS) proposed by the NASH Clinical Research Network (CRN) is an accepted scoring system to grade 3 histologic features, namely, steatosis, hepatocellular ballooning, and lobular inflammation. 11 The NAS is composed of features of active injury that potentially are reversible in the short term, and thus are recommended for use in clinical trials. Fibrosis is not included as a component of the NAS. Although the NAS correlates with the presence or absence of NASH, the diagnosis of NASH is based not on the raw NAS but on the interpretation by the histopathologist of the presence and pattern of specific histologic abnormalities on liver biopsy. 12 Although fibrosis may be present in the absence of NASH, it is a worrisome feature on liver biopsy in NAFLD because it indicates a more advanced liver disease. In addition, portal inflammation, which is not a component of the NAS, has been associated with more severe histologic injury and fibrosis in cross-sectional studies, suggesting that portal inflammation may be indicative of a worse prognosis. 15, 16 However, it remains uncertain what long-term prognostic information can be obtained from grading the different histologic features and from staging the disease in an individual patient with NAFLD. Thus, the aim of this study was to determine the long-term Prognostic RElevance of Liver Histology In NAFLD (the PRELHIN study), namely, steatosis, lobular inflammation, portal inflammation, hepatocyte ballooning, NAS, NASH, and fibrosis stage in a large number of patients with NAFLD.
Patients and Methods
This was a longitudinal, international, multicenter cohort study. Patients were identified retrospectively by reviewing the pathology database at each participating center of subjects with the pathology diagnosis of steatosis, steatohepatitis, or fatty liver. After an extensive review of the patients' medical records including all notes from clinic visits, laboratory and imaging data, and liver biopsy reports, only patients with the diagnosis of NAFLD were included in the analysis, as described later. They were untreated, consecutive patients undergoing a biopsy who met the eligibility criteria, and were recruited from 1975 to 2005 from medical centers located in 6 different countries: United States, Denmark, Australia, Iceland, Thailand, and Scotland. The time period of 1975-2005 was chosen to include a 30-year ascertainment period, and an appropriate duration of follow-up evaluation for the last patient recruited. Follow-up evaluation was extended until the end of 2012. In more than 90% of cases included the liver biopsy was performed because of persistent increases of liver enzyme levels in patients with confirmed fatty infiltration of the liver detected on imaging studies. The liver biopsy was performed to confirm the diagnosis of NAFLD after appropriate exclusion of liver disease of other etiologies, such as alcohol-induced or drug-induced liver disease, autoimmune or viral hepatitis, and cholestatic or metabolic/genetic liver disease. These other liver diseases were excluded using specific clinical, laboratory, radiographic, and/or histologic criteria. All patients had a negative history of alcohol abuse as indicated by a weekly ethanol consumption of less than 140 g in women, and less than 210 g in men. A history of alcohol consumption was investigated specifically by interviewing the patients and in many cases also by interviewing close relatives during both the first and follow-up visits. Subjects in whom an alcohol history was not provided were excluded. Serology for viral hepatitis B and C was performed before liver biopsy or during follow-up visits in all patients and all tested negative. The study was approved by the appropriate regulatory bodies at each participating center and all patients provided consent for participation in medical research.
A total of 859 patients were identified initially (Mayo Clinic, n ¼ 385; Denmark, n ¼ 169; Australia, n ¼ 119; Iceland, n ¼ 107; Thailand, n ¼ 46; and Scotland, n ¼ 33). Extensive clinical and laboratory data were collected at the time the liver biopsy was performed. A complete medical history and physical examination was performed in all patients. The ethnicity (Hispanic or Latino, and not Hispanic or Latino) and race (white, Asian, Black or African American, American Indian/Alaska native, Native Hawaiian, or other Pacific Islander) of the patients were determined based on the categories proposed by the US Department of Health and Human Services Public Health Service. 17 Body mass index (BMI) was calculated using the following formula: weight (in kilograms)/height (in meters 2 ). Laboratory evaluation included routine liver biochemistry (alanine aminotransferase and aspartate aminotransferase, total bilirubin, albumin, alkaline phosphatase, and g-glutamyl transpeptidase levels), complete blood count, fasting lipids, fasting glucose, serum ferritin, transferrin saturation, viral serology for hepatitis B and C infection, autoantibodies, a1 antitrypsin levels and phenotype, and ceruloplasmin levels. Data on medication use were collected from review of medical records.
Liver Histology
The liver biopsy slides of these 859 patients were shipped for central pathology reading and scoring to Dr David Kleiner at the National Cancer Institute, who was unaware of the patients' clinical and laboratory data. Particular attention was paid to the quality of the liver tissue and staining. In cases of slides with faded staining, new cuts of stored paraffin-embedded liver tissue and stains were obtained; when no stored tissue was available, the coverslip of the original slide was removed and the tissue was re-stained. Thus, all liver biopsy slides were of appropriate quality for confident grading and staging of the liver biopsy features. The grade and stage of several histologic features was based on the scoring system proposed by the NASH CRN as described in Supplementary Table 1. 11 A threshold of 5% of hepatocytes showing steatosis was required for the diagnosis of NAFLD. 11, 12 To control for biopsy size, the length of the biopsy specimen was measured with a hand ruler, and the number of portal areas on one cross-section was counted. Only those liver biopsy specimens that the histopathologist deemed of appropriate size and had a sufficient number of portal tracts allowing confident grading and staging were included. Biopsy specimens showing evidence of a second histologic process also were excluded. The grade of several histologic features was scored on H&E-stained tissue. The stage of fibrosis was scored on Masson's Trichrome stained tissue. The NAS was recorded as the unweighted sum of the scores for steatosis (0-3), lobular inflammation (0-3), and ballooning (0-2), thus ranging from 0 to 8. Based on the NAS, 3 NAS categories were created: NAS 2, NAS 3-4, and NAS ! 5.
11 Portal inflammation was graded on a scale of 0-2. 15 The diagnosis of NASH as determined by the reporting histopathologist was recorded and categorized as non-NASH, borderline/suspicious NASH, or definitive NASH as proposed. 12 Fibrosis was staged on a scale of 0-4.
11

Follow-Up Evaluation
Patients were followed-up at 3-to 12-month intervals after the diagnosis of NAFLD. At each visit, a complete medical history and physical examination were performed along with routine laboratory work-up to follow up their liver disease. Patients with advanced fibrosis or cirrhosis underwent endoscopy screening for gastroesophageal varices and screening for HCC at regular intervals following standard-of-care recommendations or guidelines in place at specific times as proposed by liver societies. 18, 19 The decision to perform upper-gastrointestinal endoscopy and liver imaging during the follow-up evaluation of patients with no or earlier (stages 1-2) fibrosis was decided by the treating physician in each medical center. Giving the lack of approved treatment for NAFLD, treatment recommendations specifically for NAFLD during the study period were similar in all centers and consisted of the standard recommendations to achieve and maintain appropriate body weight with increased physical activity and dietary changes. No specific dietary intervention or specific type of physical activity were used. Individuals who did not reach an outcome and whose health status was unknown for more than 12 months of reviewing their medical records were considered lost to follow-up evaluation. No patients received treatment with pioglitazone, vitamin E, or pentoxifylline at any point during the study duration, and no patients underwent bariatric surgery.
Statistical Analysis
Data are presented as median (interquartile range [IQR]) or otherwise specified, and number (percentage) of patients with a condition. The outcomes analyzed were overall mortality (death from any cause) or liver transplantation (whichever occurred first); and liver-related events (ascites [detected clinically and/or on imaging], gastroesophageal varices/ bleeding [confirmed by endoscopy], portosystemic encephalopathy [diagnosed clinically], and HCC [detected on imaging and/or biopsy]).
The cumulative overall mortality/liver transplantation and liver-related events during the follow-up evaluation were calculated using Kaplan-Meier analysis and compared by logrank testing. The liver biopsy features that were analyzed by Kaplan-Meier (unadjusted) analysis were steatosis grade, lobular inflammation grade, portal inflammation grade, ballooning grade, NAS category ( 2, 3-4, and ! 5), NASH category (non-NASH, borderline/suspicious NASH, and definitive NASH), and fibrosis stage (stages 0, 1, 2, 3, and 4). Fibrosis stage 1A, 1B, and 1C 11 were combined as stage 1 because there was no significant difference in mortality rate among the three groups (log-rank test, P ¼ .5). Borderline zone 3 and zone 1 patterns 11 were combined as borderline NASH because there was no significant difference in the mortality rate between the 2 groups (log-rank test, P ¼ .1).
Univariate (unadjusted) and multivariate (adjusted) hazard ratio (HR) estimates (relative risk) for outcomes were calculated by Cox proportional hazard regression analysis to control for the effect of potential risk factors (confounders), while taking into consideration varying lengths of follow-up evaluation. When possible, 2 models were created for each outcome analyzed: model 1 included the liver biopsy features that were statistically significant (P < .05) by univariate analysis, and model 2 included variables from model 1 plus variables that potentially may affect the outcomes such as age, sex, race, BMI, diabetes, hypertension, use of statins for at least 6 months, site, and smoking. Because it is reasonable to assume that the relationship between risk factors and outcomes may not remain stable over a long recruitment period, calendar year of liver biopsy was considered as a variable in the Cox regression models, as was the liver biopsy size, to control for the potential effect of biopsy size on the outcomes. Variables independently associated with the outcomes analyzed were identified by stepwise forward selection procedure using a threshold of a P value less than .1 for variable selection. Time at risk was from the date of liver biopsy to the date of outcome or last follow-up evaluation. Patients known to have, or who developed, any of the outcomes within 3 months of the liver biopsy procedure were eliminated a priori from the analysis. Analyses were performed using IBM SPSS Statistics version 21.0 software (IBM Corporation, Armonk, NY).
Results
Baseline Characteristics
Of the 859 patients, 240 were excluded (Supplementary Figure 1) , leaving 619 patients for analysis. Supplementary  Figure 2 illustrates the number of liver biopsies performed by calendar year period. ). There was a predominance of white race, approximately two thirds were women, and approximately a third of patients suffered from diabetes or hypertension. Table 2 describes the liver biopsy features of the patient population. The median NAS was 3.0 (IQR, 2-5) with a mean of 3.6 (SD, 1.7; range, 1-8). There was a similar proportion of patients within the 3 NAS categories; more than half had non-NASH, and almost a third had definitive NASH. Approximately half did not have fibrosis on liver biopsy, a third had fibrosis stages 1-2, and 11.5% had advanced (stages 3-4) fibrosis.
Long-Term Follow-Up Evaluation
The median duration of follow-up evaluation of the 619 patients was 12.6 years (range, 0.3-35.1 y) for a total of 7799 person-years of follow-up evaluation. A total of 97 (15.7%) patients were lost to follow-up evaluation and they had a mean follow-up period of 6.0 years (SD, 5.5 y). The type and number of outcomes in the total cohort are described in Table 3 . A total of 193 (33.2%) patients reached the outcome of mortality/liver transplantation. Cardiovascular events followed by nonliver malignancy, and complications of cirrhosis (along with HCC and liver transplantation) were the 3 most common causes of death. Twenty-six (4.2%) patients developed a total of 39 liverrelated events. Development of gastroesophageal varices with or without bleeding, ascites, and portosystemic encephalopathy were the predominant liver-related events.
Long-Term Outcomes Based on Liver Histology
The cumulative probability (unadjusted) obtained by Kaplan-Meier analysis of mortality/liver transplantation and liver-related events through the different liver biopsy features is described in Table 4 , and illustrated in Supplementary Figures 3 and 4 . There was a significantly different survival free of liver transplantation and survival free of liver-related events according to ballooning grade, portal inflammation grade, the NASH categories, and fibrosis stage, but not among steatosis grade, lobular inflammation grade, or NAS categories.
Fibrosis stage correlated significantly with portal inflammation grade (r ¼ 0.62; P < .001), ballooning grade (r ¼ 0.60; P < .001), and NASH category (r ¼ 0.70; P < .001). Among the 462 patients with portal inflammation , 285.9; P < .001). The univariate-unadjusted hazard ratios for each histologic feature for the outcome of mortality/liver transplantation are described in Supplementary Table 2 and the multivariate-adjusted hazard ratios are described in Table 5 . Fibrosis stage was the only histologic feature independently associated with this outcome along with age, presence of diabetes, current smoking, and use of statins. The univariate-unadjusted hazard ratios for each histologic NOTE. Data are presented as the number (%) of patients with a condition. feature for the outcome of liver-related events are described in Supplementary Table 3 , and the multivariate-adjusted hazard ratios are described in Table 6 . Fibrosis stage was the only variable independently associated with this outcome. Liver-related mortality/liver transplantation.
Deaths caused by complications of cirrhosis, HCC, or liver transplantation occurred in 18 of 193 patients (9.3%) ( 
Long-Term Outcomes of Individuals Without Advanced Fibrosis
Because patients with stages 3 and 4 fibrosis are expected to have a higher mortality or need liver transplantation and are expected to develop more liver-related events, we performed an additional analysis of the long-term outcomes of individuals with earlier disease. For this, the 71 patients with advanced fibrosis (stages 3 or 4) were eliminated, leaving a total of 548 patients without (stage 0) or mild (stages 1-2) fibrosis. Among them, 152 (27.7%) reached the outcome of mortality/liver transplantation. The cumulative probability (unadjusted) obtained by Kaplan-Meier analysis of mortality/liver transplantation in this cohort is described in Supplementary 
Long-Term Outcomes of Individuals With NASH Versus Non-NASH
Because NASH as compared with non-NASH is perceived as being associated with a worse prognosis, additional analyses were performed separately in non-NASH and NASH (borderline plus definitive) while considering the presence or absence of fibrosis. Survival free of liver transplantation in patients with non-NASH was significantly lower in patients with fibrosis as compared with those without fibrosis (P < .001); in the NASH group a similar significantly lower survival free of liver transplantation was found among patients with fibrosis as compared with those without fibrosis (P ¼ .018) (Supplementary Table 6 ). This lower survival free of liver transplantation in patients with increased fibrosis regardless of having NASH or non-NASH is illustrated in Figure 1 . Regarding the outcome of liver-related events, no significant difference was found, although there was a trend (P ¼ .07) for lower survival free of liver-related events among those with NASH and fibrosis as compared with those with NASH without fibrosis (Supplementary Table 6 ).
Discussion
Our study showed, first, fibrosis stage independently, and regardless of the presence or severity of other histologic features, is the most relevant liver biopsy feature associated with overall-and liver-related mortality/liver transplantation or liver-related events. This effect was seen even with the earliest stages of fibrosis detectable by microscopic examination, and even when individuals with advanced (fibrosis stages 3-4) disease were excluded. Second, the presence of fibrosis rather than the histologic diagnosis of NASH or non-NASH is associated with a higher mortality rate and a higher rate of liver-related events. Third, the NAS does not on its own provide any long-term prognostic information. In addition, our results validate the pathologists' practice of staging fibrosis on biopsy into multiple categories and provides prognostic meaning for early stage disease-something that has not been shown in other chronic liver diseases. The results of our study are directly relevant for patient management, counseling, and monitoring. The absence of liver fibrosis on liver biopsy indicates a lower likelihood of dying or developing liver-related complications within 1 or 2 decades. On the contrary, the presence of fibrosis identifies the subgroup of individuals with NAFLD who need to make a concerted effort to achieve and maintain appropriate body weight, optimize metabolic control, and be offered enrollment in clinical trials aimed at preventing fibrosis development or reducing fibrosis progression. In our patient population, 38% were diabetic, 31% had hypertension, 20% were current or former smokers, and the most common cause of death was cardiovascular (38%). Although these associations with NAFLD and NASH are not novel 6 we were able to show that diabetes and smoking, along with fibrosis, age, and absence of statin use, contribute to mortality and underscore the need for a comprehensive approach to patient management.
The results of this study also are relevant for the design and interpretation of clinical trials. Improvement in the NAS often is recommended and used as the primary end point to determine treatment efficacy in treatment trials. 20 In our study, the NAS on its own did not provide any long-term prognostic information, although some preliminary data suggested an association of NAS improvement with fibrosis regression in the short term (2 years). 21 Thus, more data are needed to understand whether improvement in the NAS improves the long-term prognosis of NAFLD. 22 It frequently is claimed that NASH but not simple steatosis is associated with a worse long-term prognosis. The results of our study would suggest that this dictum is not true, although the fact that only 43 patients diagnosed with definite or borderline NASH had fibrosis stage 0 limited the strength of this observation. Long-term prognosis in our cohort depended less on a diagnosis of NASH or non-NASH than on whether or not the liver biopsy showed fibrosis ( Figure 1 ). Thus, for the purpose of assessing the long-term prognosis, the focus should be on fibrosis stage while other histologic findings may have importance for understanding disease pathophysiology and short-term disease progression/regression as noted earlier. Most patients with non-NASH have steatosis with little or no inflammation; of the 335 patients with non-NASH in our study, 248 (74%) had fibrosis stage 0, ballooning grade 0, and grade 0 or 1 for portal or lobular inflammation. The etiology of fibrosis in patients with non-NASH is not entirely clear, although we would hypothesize that these cases represent a form of NASH in remission. Placebo-treated groups in clinical trials of NASH have shown that a significant minority of patients may lose the diagnostic changes of NASH. 23 Our study reproduced observations from cross-sectional studies that portal inflammation correlates significantly with advanced liver fibrosis. 15, 16 Our study extended these observations to show that although portal inflammation is not of significant long-term prognostic relevance when adjusted for the severity of liver fibrosis, it did show significance in univariate analysis. Ballooning injury showed a similar pattern with univariate significance for the outcomes analyzed that also was lost when adjusted for liver fibrosis. Although the long-term prognostic significance of portal inflammation, ballooning, and NASH category was lost when fibrosis stage was considered, our univariate analysis showed an association between these features and longterm outcomes, suggesting that such features may play a larger role in short-term disease progression, an idea supported by recent data from the NASH CRN. 24, 25 The main strengths of our study were the large number of patients included; the long-term follow-up period averaged more than 12 years per patient and up to 35 years in some cases; complete follow-up evaluation in the vast majority of patients (84.3%); having a liver biopsy that confirmed the diagnosis of NAFLD in every case; having a single experienced liver pathologist grading and staging the liver biopsy features exclusively for the purpose of this study; and the use of a scoring system for grading and staging the biopsy features that currently is accepted widely in NAFLD. A new histologic scoring system in NAFLD recently was proposed, 26 but studies are needed to determine their long-term prognostic relevance. Table 6 ).
Our study had some limitations, most of which were inherent to retrospective studies, including the lack of a specific treatment protocol with diet and exercise similar in all centers, and the lack of a specific protocol for patient follow-up evaluation with regard to endoscopy and imaging procedures in noncirrhotic patients, and thus it is possible that the number of liver-related events in our study was underestimated. Also, a 30-year ascertainment period witnessed many changes in the management of the 3 most common causes of death in our cohort, and although all multivariate analyses were adjusted by calendar year of liver biopsy, we were not able to adjust for specific treatment modalities other than statin use. Of note, our cohort included only 1 patient who underwent liver transplantation, although 17 individuals died of liver disease, suggesting that comorbid conditions may have precluded transplantation. Cirrhosis resulting from NASH is becoming a more common indication for liver transplantation and it is possible that the use of liver transplantation may be higher in a modern prospectively followed up cohort. Our study also was limited by the over-representation of white race and under-representation of some ethnic/racial groups including Hispanics and blacks/African Americans. Finally, although having an adequate liver biopsy available for review was one of the strengths of our study, it created a potential accrual bias that was difficult to control for, because it was a key to our study design.
In conclusion, liver fibrosis is the most important liver biopsy feature associated with increased overall and liverrelated mortality and increased likelihood of developing liver-related complications. This association of liver fibrosis with long-term outcomes was independent of the presence and severity of other histologic features and the NAFLD activity score. The presence and severity of fibrosis regardless of the diagnosis of NASH dictated the long-term prognosis in patients with NAFLD. These results are relevant for patient counseling and monitoring, and for the interpretation and design of clinical trials. 
